Vertaling van "cancer society cancer prevention study " (Frans → Nederlands) :

La figure 1 illustre le risque relatif de décès après avoir arrêté de fumer selon l'American Cancer Society, Cancer Prevention Study 2 (étude ACS/CPS2 ; données fournies gracieusement par le Dr Thun).
Afbeelding 1 geeft het relatieve risico op sterfte weer na rookstop, uit de American Cancer Society, Cancer Prevention Study 2.9 Het risico bij vrouwen is kleiner omdat ze vroeger minder hebben gerookt.14 Het risico op sterfte is kort na de rookstop groter dan verwacht: een gevolg van patiënten die stoppen vanwege een ziekte.

Spontaneous cessation rate: 2.5% OR counselling only: 1.73 Incremental OR NRT gum (relative to counselling only): 1.63 Incremental OR NRT patch (relative to counselling only): 1.79 Incremental OR NRT spray (relative to counselling only): 2.35 Incremental OR NRT inhaler (relative to counselling only): 2.14 Incremental OR Buproprion (relative to counselling only): 2.30 % of smokers still under treatment after the first month: 50% (range 40-60% in sensitivity analysis) % of smokers still under treatment after the second month: 20% (range 15-25% in sensitivity analysis) Lifetime relapse probability after one year of abstinence: 35% (range 10-50% in sensitivity analysis) Effect of smoking cessation on mortality derived from the results of the American Cancer Society Prevention Study II. The mortality rate for former smokers was projected by calculating a weighted average of the incremental differentials between mortality rates of neversmokers and smokers, weighted according to the duration of abstinence.
Spontaneous cessation rate: 2.5% OR counselling only: 1.73 Incremental OR NRT gum (relative to counselling only): 1.63 Incremental OR NRT patch (relative to counselling only): 1.79 Incremental OR NRT spray (relative to counselling only): 2.35 Incremental OR NRT inhaler (relative to counselling only): 2.14 Incremental OR bupropion (relative to counselling only): 2.30 % of smokers still under treatment after the first month: 50% (range 40-60% in sensitivity analysis) % of smokers still under treatment after the second month: 20% (range 15-25% in sensitivity analysis) Lifetime relapse probability after one year of abstinence: 35% (range 10-50% in sensitivity analysis) Effect of smoking cessation on mortality derived from the results of the American Cancer Society Prevention Study II. The mortality rate for former smokers was projected by calculating a weighted average of the incremental differentials between mortality rates of neversmokers and smokers, weighted according to the duration of abstinence.

La Commission a également financé le projet EUROSKIN (European society of skin cancer prevention – Société européenne de prévention du cancer de la peau), qui porte sur la prévention primaire, la mise en œuvre de normes de certification européennes pour les solariums, la thérapie cellulaire, les carcinomes et le dépistage.
Daarnaast is in het zesde kaderprogramma het project EUROSKIN (Europees netwerk voor huidkankerpreventie) gefinancierd ter ondersteuning van initiatieven op het gebied van primaire preventie, Europese certificeringsnormen voor zonnebanken, epidermale stamcellen en kanker, en huidkankerscreening.

Une autre étude 13 a utilisé un modèle similaire : lÊHECOS. DÊautres encore utilisaient la différence de mortalité totale entre les fumeurs et les nonfumeurs pour estimer les années de vie gagnées après le sevrage tabagique, par exemple lÊEtude sur la prévention du cancer dans 25 états de lÊAmerican Cancer Society 14,15 .
13 Andere onderzoeken gebruikten het geobserveerde verschil in totale sterfte tussen rokers en niet-rokers om de gewonnen levensjaren na rookstop in te schatten, bijvoorbeeld op basis van de gegevens van de American Cancer SocietyÊs 25-state Cancer Prevention Study. 14,15

Les résultats de cette étude s'opposent à ceux de la Beta-Carotene (ATBC) Cancer Prevention Study finlandaise qui indiquent que le taux de vitamine D dans le sang de fumeurs de sexe masculins est associé à un risque accru de cancer du pancréas.
De resultaten uit dit onderzoek staan in contrast met wat blijkt uit de Finse Beta-Carotene (ATBC) Cancer Prevention Study, waarbij de vitamine D-bloedwaarde bij mannelijke rokers gelinkt wordt aan een verhoogd risico op pancreaskanker.

Un premier essai randomisé contrôlé : Multivitamins in the Prevention of Cancer in Men - The Physicians' Health Study II Randomized Controlled Trial (plus de 14 000 personnes, 4 ans de suivi) (1).
Een eerste gerandomiseerde gecontroleerde studie was de Multivitamins in the Prevention of Cancer in Men: The Physicians' Health Study II Randomized Controlled Trial (meer dan 14 000 mensen, 4 jaar follow-up) (1).

Lee IM, Cook NR, Gaziano JM et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women’s Health Study. JAMA
multivitamines: niet werkzamer dan foliumzuur, alleen in de preventie van neuraalbuisdefecten, vroeggeboorte en

31. Gaziano JM , Glynn RJ, Christen WG et al. Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial.
31.Gaziano JM , Glynn RJ, Christen WG et al. Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial.

27. Lee IM, Cook NR, Gaziano JM et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women’s Health Study.
27.Lee IM, Cook NR, Gaziano JM et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women’s Health Study.

15. ATBC (The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group).
15.ATBC (The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group).